MT-1 Research Overview: The Melanocortin Receptor Peptide
MT-1, also known in the scientific literature as afamelanotide or NDP-α-MSH, is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) developed at the University of Arizona in the 1980s by researchers including Mac Hadley and Victor Hruby. It was the first of the melanotan-class peptides, later followed by the structurally distinct Melanotan II.
This article reviews MT-1's proposed receptor mechanism and summarizes the published research, including how its evidence base compares with the more commonly discussed Melanotan II.
What Is MT-1?
MT-1 is a metabolically stable analog of the naturally occurring 13-amino-acid hormone α-MSH, which is produced from the precursor protein pro-opiomelanocortin (POMC) and plays a role in regulating skin pigmentation, energy balance, and inflammatory signaling. Researchers modified the native α-MSH sequence to improve its stability and duration of action, producing the compound designated Melanotan-I.
Structurally, MT-1 is distinguished from Melanotan-II by its linear (non-cyclic) structure and by its receptor selectivity profile, both of which relate directly to differences in the research findings associated with each compound.
Receptor Mechanism
The melanocortin system consists of five receptor subtypes (MC1R–MC5R). MT-1 is described in structural pharmacology research as acting predominantly at MC1R, the receptor most directly responsible for stimulating eumelanin production in melanocytes. Recent structural biology work using cryo-EM has characterized how afamelanotide engages MC1R at the molecular level, including calcium-mediated hormone recognition and G-protein interaction, providing a detailed mechanistic basis for its pigmentary effects. (bioRxiv)
This MC1R-predominant profile is a key research distinction from Melanotan-II, which engages a broader range of melanocortin receptors, including those linked to centrally mediated effects outside of pigmentation.
Clinical Research Findings
MT-1's most substantial clinical evidence comes from research in erythropoietic protoporphyria (EPP), a rare photosensitivity disorder. Two Phase 3 randomized controlled trials reported significant increases in pain-free sun exposure among EPP patients receiving MT-1 compared with placebo, findings that supported its approval in several countries specifically for EPP management via subcutaneous implant administered by a healthcare professional. (Superpower)
Because MT-1 is not orally bioavailable and has a short half-life as a peptide, its approved clinical use relies on an implant delivery method administered roughly every two months in a clinical setting — a very different administration context from generalized research use. (PMC)
How MT-1 Differs From Melanotan-II in the Research Literature
Published comparisons of the melanotan class describe a meaningful divergence in evidence quality between the two compounds. MT-1 (afamelanotide) has completed Phase 3 randomized controlled trials with defined efficacy endpoints. Melanotan-II, by contrast, has no completed efficacy RCTs and has instead been associated in case reports with adverse events including changes in nevi, melanoma, severe toxicity, and vascular events. (Superpower)
This distinction matters for anyone reviewing melanotan-related research: findings, safety data, and mechanisms reported for one compound do not automatically apply to the other, given their different receptor engagement profiles and different depth of controlled clinical study.
Regulatory Status
Afamelanotide (MT-1) has received regulatory approval in certain jurisdictions specifically for EPP, administered via implant under medical supervision. It is not approved by the U.S. Food and Drug Administration for general use, and research-grade MT-1 sold for laboratory purposes is a distinct product from the approved implant formulation, intended strictly for in-vitro and analytical research rather than any therapeutic application.
The Bottom Line
MT-1 carries one of the more substantial controlled-trial evidence bases among melanocortin peptides, anchored by completed Phase 3 research in EPP and a well-characterized MC1R-selective mechanism supported by recent structural biology data.
That evidence, however, is specific to a defined clinical population and a defined implant-based delivery method under medical supervision. It should not be generalized to other routes of administration or to the structurally distinct Melanotan-II, which carries a substantially different — and more concerning — safety literature.
Educational Disclaimer
This article is provided for educational and scientific informational purposes only. It is not medical advice and does not provide instructions for human use, dosing, administration, diagnosis, treatment, or prevention of any disease. MT-1 sold by King's Compounds is intended strictly for laboratory research and analytical purposes and is not the approved implant medication.